Small study looks only at a cardiac biomarker; findings are in line with reduced myocarditis risk in mRNA COVID vaccines ...

(NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the ...

Moderna said on Wednesday it would stop developing its experimental vaccine to prevent cytomegalovirus, a virus that can ...

While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients ...

Moderna is halting development of an mRNA vaccine for congenital cytomegalovirus after its candidate failed to protect women ...

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...

Moderna’s oncology pipeline also includes a Merck-partnered personalized cancer vaccine called intismeran autogene or ...

A key question for investors going forward will be whether Moderna's other latent virus vaccines for Epstein-Barr and shingles can succeed after the failure of the CMV program.

New research shows Moderna and Pfizer’s mRNA vaccines may prime the immune system to attack cancer—even better than some ...

Moderna halts late-stage CMV vaccine trial after unmet goals but maintains 2025 financial outlook. Read more here.

Moderna said its experimental vaccine for cytomegalovirus failed in a key trial, a significant setback for a company already ...

Moderna Inc. has taken a hit to its pipeline after its vaccine for cytomegalovirus (CMV) failed a late-stage trial.